OUTLOOK THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
OUTLOOK THERAPEUTICS, INC. (OTLK) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $0.57 per share for the 9-month period ending 2021-06-30, per its 10-Q filed 2021-08-13.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2021-08-13
- OUTLOOK THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2020-12-31 was $0.54, a 45.45% decline year-over-year.
- OUTLOOK THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2020-03-31 was $0.72, a 88.68% decline year-over-year.
- OUTLOOK THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2019-12-31 was $0.99.
- OUTLOOK THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2019-03-31 was $6.36.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month |
|---|---|---|---|
| 2021-06-30 | $0.57 10-Q · filed 2021-08-13 | ||
| 2021-03-31 | $0.56 10-Q · filed 2021-05-14 | ||
| 2020-12-31 | $0.54 10-Q · filed 2021-02-16 | ||
| 2020-06-30 | $0.71 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $0.72 10-Q · filed 2020-05-15 | $0.72 10-Q · filed 2021-05-14 | |
| 2019-12-31 | $0.99 10-Q · filed 2021-02-16 | ||
| 2019-06-30 | $4.70 10-Q · filed 2020-08-14 | ||
| 2019-03-31 | $6.36 10-Q · filed 2020-05-15 | ||
| 2018-06-30 | $0.52 10-Q · filed 2018-08-14 | ||
| 2018-03-31 | $0.73 10-Q · filed 2018-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |